» Articles » PMID: 24114662

PU-H71 Effectively Induces Degradation of IκB Kinase β in the Presence of TNF-α

Overview
Publisher Springer
Specialty Biochemistry
Date 2013 Oct 12
PMID 24114662
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

This study is to determine if PU-H71, a heat shock protein inhibitor, induces killing of malignant breast cells together with treatment of tumor necrosis factor-α (TNF-α). The related molecular mechanisms were also studied. A primary mammary epithelial cell line HMEC2595 cells and the highly metastatic breast cell line MDA-MB-231, the HER2-positive BT-474 cells, and the ER-positive MCF7 cells were treated with PU-H71 in the presence or absence of TNF-α. The effects of PU-H71 and TNF-α treatments on cells viabilities and on intracellular signaling pathway proteins were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, apoptosis assays, immunoblot assays, and luciferase assays. It was found that TNF-α enhances the toxic effects of PU-H71 on tumor cells but not normal cells. PU-H71 treatments lead to degradation of IKKβ. Moreover, PU-H71 down-regulates the NF-κB transcriptional activity induced by TNF-α treatment. The experimental results indicated PU-H71 effectively induces cell killing of malignant breast cells in the presence of TNF-α, possibly through a mechanism related to degradation of IKKβ. It is suggested that combination of PU-H71 and TNF-α treatments might be an effective therapeutic strategy of breast malignancies.

Citing Articles

HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.

Kale S, Korcum A, Dundar E, Erin N Naunyn Schmiedebergs Arch Pharmacol. 2019; 393(2):253-262.

PMID: 31522240 DOI: 10.1007/s00210-019-01725-z.


First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.

Speranza G, Anderson L, Chen A, Do K, Eugeni M, Weil M Invest New Drugs. 2017; 36(2):230-239.

PMID: 28808818 PMC: 6126370. DOI: 10.1007/s10637-017-0495-3.


Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

Goldstein R, Yang S, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K J Clin Invest. 2015; 125(12):4559-71.

PMID: 26529251 PMC: 4665772. DOI: 10.1172/JCI80714.

References
1.
Wajant H, Pfizenmaier K, Scheurich P . Tumor necrosis factor signaling. Cell Death Differ. 2003; 10(1):45-65. DOI: 10.1038/sj.cdd.4401189. View

2.
Wu M, Ao Z, Prasad K, Wu R, Schlossman S . IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science. 1998; 281(5379):998-1001. DOI: 10.1126/science.281.5379.998. View

3.
Zuo J, Bi C, Fan Y, Buac D, Nardon C, Daniel K . Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes. J Inorg Biochem. 2012; 118:83-93. PMC: 3676669. DOI: 10.1016/j.jinorgbio.2012.10.006. View

4.
Neckers L, Ivy S . Heat shock protein 90. Curr Opin Oncol. 2003; 15(6):419-24. DOI: 10.1097/00001622-200311000-00003. View

5.
Broemer M, Krappmann D, Scheidereit C . Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. Oncogene. 2004; 23(31):5378-86. DOI: 10.1038/sj.onc.1207705. View